One-Shot gene therapy could end frequent eye injections for wet AMD
Disease control
Not yet recruiting
This study tests a gene therapy called EXG202 for people with wet age-related macular degeneration (nAMD). The goal is to see if a single injection can safely deliver a protein that blocks harmful blood vessel growth, potentially reducing the need for repeated eye injections. The…
Phase: PHASE1, PHASE2 • Sponsor: Guangzhou Jiayin Biotech Ltd • Aim: Disease control
Last updated May 17, 2026 10:38 UTC